Morgan Stanley Downgrades Adobe, Workday as AI Transition Raises Growth Concerns 
Asian Currencies Hold Steady as Middle East Tensions Boost US Dollar, Oil Concerns 
Australia Jobs Surge in June Strengthens Case for More RBA Rate Hikes 
Belimo H1 Sales Surge as AI Data Center Cooling Drives More Than Half of Growth 
Oil Prices Extend Four-Day Rally as U.S.-Iran Conflict and Red Sea Threats Raise Supply Fears 
Alphabet Q2 Earnings Beat Estimates as AI Spending, Google Cloud Growth Fuel Outlook 
Chalco Shares Jump as Chinalco Plans Up to $300 Million Stake Increase 
ASEAN Ministers Warn Middle East Conflict Threatens Regional Stability and Energy Security 
European Stocks Slip as Earnings, UK Inflation and ECB Decision Keep Investors on Edge 
US-Iran Conflict Escalates as Gulf Attacks Threaten Global Oil Supply 
Gold Price Climbs Above $4,130 as Middle East Tensions Boost Safe-Haven Demand 
Trump Set to Unveil New Tariffs on Dozens of Countries as Global 10% Duty Nears Expiration 
Wistron Opens $700M Texas AI Factory to Build Nvidia GB300 Superchips 
Pakistan Seeks $10 Billion U.S. Exchange Stabilization Fund to Boost Forex Reserves 
Houthi Naval Blockade on Saudi Arabia Escalates Iran Conflict, Threatens Global Oil Supply 
Ryanair Warns Summer Airfares May Stay Lower as Quarterly Profit Misses Estimates 
US Dollar Pauses Rally as Middle East Tensions Support Safe-Haven Demand 
CJ Cheiljedang, South Korea’s largest food and beverage conglomerate, is set to buy Batavia Biosciences, a Dutch bio firm for $226 million or about €195 million. It was reported that the deal came not long after the company revealed its $8.5 billion growth plan for its four major business areas.
CJ Cheiljedang which is a subsidiary of CJ Group announced on Monday, Nov. 8, that it will be acquiring the said Dutch biotech company as part of its plan to broaden its presence in the contract biopharmaceutical production market.
According to The Korea Economic Daily, the company’s board of directors already gave the “go” signal for the acquisition of 75.8% share in Batavia Biosciences. It was reportedly posted in the regulatory filing that this deal is worth ₩267.7 billion or $226 million.
Moreover, CJ Cheiljedang shared it will buy 50,807 shares in the Leiden, Netherlands-headquartered biotech firm and this includes 13,007 new shares at €3,844 per share. It should be noted that the companies’ acquisition deal is still subject to approval by regulatory authorities in South Korea and the Netherlands.
Once the transactions are complete, CJ will immediately work on the expansion of its “red bio” business which refers to the line of work in the medical and pharmaceutical fields. “There’s no dominant leader in the gene therapy treatment market,” an official at CJ said in a statement. “We want to grow big in this area as soon as possible.”
Batavia Biosciences is based in the Netherlands but is has research and development (R&D) centers and sales offices in Hong Kong and Boston, U.S.A. It was founded by the researchers of Janssen Pharmaceuticals in 2010 and mainly worked on cell and gene therapies under CDMO or Contract Development and Manufacturing Organization program. It has extensive experience in virus vaccine, viral vector, monoclonal antibody, microbial vaccine, and recombinant protein development.
Finally, BioPharma reported that with its acquisition of Batavia Biosciences, it appears that CJ Group is directing its attention back to its pharmaceutical business. After unloading its healthcare unit to Kolmar Korea in 2018, CJ seems to have revived its interest in expanding in the biopharma line.
